A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
Phase 1
Terminated
- Conditions
- HypogonadismHypogonadism, MaleGonadal DisordersEndocrine System DiseasesTestosterone Deficiency
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- TesoRx Pharma, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT03335254
- Locations
- 🇺🇸
California Clinical Trials, Glendale, California, United States
Oral Testosterone for the Treatment of Hypogonadism in Males
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- TesoRx Pharma, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT02222558
- Locations
- 🇺🇸
San Diego Sexual Medicine, San Diego, California, United States
Oral Testosterone for the Treatment of Hypogonadism
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- TesoRx Pharma, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT01717768
- Locations
- 🇺🇸
Urology Group of Southern California, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath